Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Taysha Gene Therapies (TSHA) Net Income towards Common Stockholders: 2022-2025

Historic Net Income towards Common Stockholders for Taysha Gene Therapies (TSHA) over the last 4 years, with Sep 2025 value amounting to -$32.7 million.

  • Taysha Gene Therapies' Net Income towards Common Stockholders fell 28.24% to -$32.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$99.9 million, marking a year-over-year decrease of 338.82%. This contributed to the annual value of -$89.3 million for FY2024, which is 19.96% up from last year.
  • Per Taysha Gene Therapies' latest filing, its Net Income towards Common Stockholders stood at -$32.7 million for Q3 2025, which was down 21.77% from -$26.9 million recorded in Q2 2025.
  • Over the past 5 years, Taysha Gene Therapies' Net Income towards Common Stockholders peaked at $47.7 million during Q4 2023, and registered a low of -$117.1 million during Q3 2023.
  • For the 3-year period, Taysha Gene Therapies' Net Income towards Common Stockholders averaged around -$25.6 million, with its median value being -$24.1 million (2024).
  • The largest annual percentage gain for Taysha Gene Therapies' Net Income towards Common Stockholders in the last 5 years was 186.68% (2023), contrasted with its biggest fall of 341.39% (2023).
  • Over the past 4 years, Taysha Gene Therapies' Net Income towards Common Stockholders (Quarterly) stood at -$55.1 million in 2022, then surged by 186.68% to $47.7 million in 2023, then plummeted by 139.35% to -$18.8 million in 2024, then decreased by 28.24% to -$32.7 million in 2025.
  • Its last three reported values are -$32.7 million in Q3 2025, -$26.9 million for Q2 2025, and -$21.5 million during Q1 2025.